NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAVUDINE; LAMIVUDINE is a fixed-dose combination oral antiretroviral tablet containing two nucleoside reverse transcriptase inhibitors (NRTIs). This combination is indicated for the treatment of HIV-1 infection in adults and pediatric patients. The drugs work by inhibiting reverse transcriptase, blocking viral replication.
PRE_LAUNCH
Pre-launch status indicates early-stage team building with focus on regulatory completion, manufacturing scale-up, and market preparation activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STAVUDINE; LAMIVUDINE during pre-launch offers entry-level to mid-career professionals exposure to regulatory completion, market strategy development, and commercial launch execution in the HIV therapeutic space. This is an opportunity to build skills in a mature but essential therapeutic area with established patient populations and reimbursement pathways.
Regulatory Affairs Specialist
Worked on STAVUDINE; LAMIVUDINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.